{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:29:10Z","timestamp":1778682550860,"version":"3.51.4"},"reference-count":41,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Frontline Gastroenterol"],"accepted":{"date-parts":[[2019,4,29]]},"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:p>Alcoholic hepatitis (AH) is an acute deterioration in liver function seen in the context of prolonged excessive alcohol consumption and is characterised by the rapid onset of jaundice. The diagnosis of AH has been controversial for many years: it is now accepted that there are clear clinical criteria which can be used to diagnose AH without the need for a liver biopsy. Corticosteroids remain the only treatment proven to be effective in reducing short-term mortality in severe AH; abstinence from alcohol is the most important factor in determining long-term survival. It is recommended a trial of corticosteroid therapy is considered only in those patients with high baseline \u2018static\u2019 scores (Glasgow Alcoholic Hepatitis score and model for end-stage liver disease). Response to corticosteroid therapy should be assessed using a \u2018dynamic\u2019 score such as the Lille score at day 7, with corticosteroids continuing only in patients with a favourable score. Infection and acute kidney injury are associated with poorer outcomes in AH. Early screening for and treatment of infection is recommended with antibiotic therapy overlapping with any subsequent corticosteroid treatment. A biomarker which predicts benefit from corticosteroids at baseline would avoid a trial of therapy to determine response. More efficacious therapeutic options for AH patients are required with N-acetylcysteine, granulocyte colony stimulating factor, faecal microbiota transplantation and routine antibiotics showing promise, but adequate controlled trials are needed to confirm efficacy. Liver transplant has an emerging role for some patients with severe AH not responding to corticosteroids and is likely to become more acceptable with improved methods of patient selection.<\/jats:p>","DOI":"10.1136\/flgastro-2018-101104","type":"journal-article","created":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T17:51:03Z","timestamp":1558461063000},"page":"133-139","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Recent advances in alcoholic hepatitis"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct02281929","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jennifer","family":"Veryan","sequence":"first","affiliation":[{"name":"Liver Unit, Glasgow Royal Infirmary, Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7293-2574","authenticated-orcid":false,"given":"EH","family":"Forrest","sequence":"additional","affiliation":[{"name":"Liver Unit, Glasgow Royal Infirmary, Glasgow, Glasgow, UK"},{"name":"College of Medicine, Veterinary and Life Sciences, University of Glasgow, Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,5,21]]},"reference":[{"key":"2025090709073938000_11.2.133.1","unstructured":"ISD Scotland . Alcohol-related Hospital statistics Scotland 2017\/18, 2018. Available: https:\/\/www.isdscotland.org\/Health-Topics\/Drugs-and-Alcohol-Misuse\/Publications\/2018-11-20\/2018-11-20-ARHS-Report.pdf [Accessed 27 Jan 2019]."},{"key":"2025090709073938000_11.2.133.2","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1056\/NEJMoa1412278","article-title":"Prednisolone or pentoxifylline for alcoholic hepatitis","volume":"372","author":"Thursz","year":"2015","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025090709073938000_11.2.133.3","doi-asserted-by":"crossref","unstructured":"Hamid R , Forrest EH . Is histology required for the diagnosis of alcoholic hepatitis? A review of published randomised controlled trials. Gut 2011;60(Suppl 1).doi:10.1136\/gut.2011.239301.492","DOI":"10.1136\/gut.2011.239301.492"},{"key":"2025090709073938000_11.2.133.4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.02.042"},{"key":"2025090709073938000_11.2.133.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.018"},{"key":"2025090709073938000_11.2.133.6","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2017.469"},{"key":"2025090709073938000_11.2.133.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.11.017"},{"key":"2025090709073938000_11.2.133.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2008.01783.x"},{"key":"2025090709073938000_11.2.133.9","unstructured":"Forrest EH , Atkinson SR , Richardson P , et al . ACG clinical guideline for alcoholic liver disease: the MELD threshold for corticosteroid treatment has yet to be established. Am J Gastroenterol 2018;11."},{"key":"2025090709073938000_11.2.133.10","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21607"},{"key":"2025090709073938000_11.2.133.11","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/ajg.2016.539","article-title":"A Day-4 Lille model predicts response to corticosteroids and mortality in severe alcoholic hepatitis","volume":"112","author":"Garcia-Saenz-de-Sicilia","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"2025090709073938000_11.2.133.12","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.044"},{"key":"2025090709073938000_11.2.133.13","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/hep.29240","article-title":"Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: a prospective study","volume":"66","author":"Louvet","year":"2017","journal-title":"Hepatology"},{"key":"2025090709073938000_11.2.133.14","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.04.062"},{"key":"2025090709073938000_11.2.133.15","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1053\/j.gastro.2016.12.019","article-title":"In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and Infection-Related Mortality, and Is Associated With High Circulating Levels of Bacterial DNA","volume":"152","author":"Vergis","year":"2017","journal-title":"Gastroenterology"},{"key":"2025090709073938000_11.2.133.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.09.011"},{"key":"2025090709073938000_11.2.133.17","doi-asserted-by":"publisher","DOI":"10.1002\/lt.25328"},{"key":"2025090709073938000_11.2.133.18","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jhep.2014.11.003","article-title":"Prognosis of treated severe alcoholic hepatitis in patients with gastrointestinal bleeding","volume":"62","author":"Rudler","year":"2015","journal-title":"J Hepatol"},{"key":"2025090709073938000_11.2.133.19","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00428-018-2330-4","article-title":"Histological activity score on baseline liver biopsy can predict non-response to steroids in patients with severe alcoholic hepatitis","volume":"472","author":"Shasthry","year":"2018","journal-title":"Virchows Arch"},{"key":"2025090709073938000_11.2.133.20","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/apt.14564","article-title":"Microvesicles in hepatic and peripheral vein can predict nonresponse to corticosteroid therapy in severe alcoholic hepatitis","volume":"47","author":"Sukriti","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2025090709073938000_11.2.133.21","doi-asserted-by":"crossref","unstructured":"Das S , Hussain MS , Maras JS , et al . Modification patterns of urinary albumin correlates with serum albumin and outcome in severe alcoholic hepatitis. J Clin Gastroenterol 2018.doi:10.1097\/MCG.0000000000000990","DOI":"10.1097\/MCG.0000000000000990"},{"key":"2025090709073938000_11.2.133.22","doi-asserted-by":"crossref","unstructured":"Forrest E , Storey N , Rohit S , et al . Baseline neutrophil to lymphocyte ratio can identify favourable corticosteroid response in alcoholic hepatitis. J Hepatol 2017;66.doi:10.1016\/S0168-8278(17)30459-2","DOI":"10.1016\/S0168-8278(17)30459-2"},{"key":"2025090709073938000_11.2.133.23","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jhep.2018.02.022","article-title":"The prognostic value of acute-on-chronic liver failure during the course of severe alcoholic hepatitis","volume":"69","author":"Serst\u00e9","year":"2018","journal-title":"J Hepatol"},{"key":"2025090709073938000_11.2.133.24","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1111\/liv.12786","article-title":"The use of beta-blockers is associated with the occurrence of acute kidney injury in severe alcoholic hepatitis","volume":"35","author":"Serst\u00e9","year":"2015","journal-title":"Liver Int"},{"key":"2025090709073938000_11.2.133.25","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1053\/j.gastro.2015.12.038","article-title":"Intensive enteral nutrition is ineffective for patients with severe alcoholic hepatitis treated with corticosteroids","volume":"150","author":"Moreno","year":"2016","journal-title":"Gastroenterology"},{"key":"2025090709073938000_11.2.133.26","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.06.006"},{"key":"2025090709073938000_11.2.133.27","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1053\/j.gastro.2018.05.011","article-title":"Corticosteroids reduce risk of death within 28 days for patients with severe alcoholic hepatitis, compared with pentoxifylline or Placebo\u2014a meta-analysis of individual data from controlled trials","volume":"155","author":"Louvet","year":"2018","journal-title":"Gastroenterology"},{"key":"2025090709073938000_11.2.133.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1101214"},{"key":"2025090709073938000_11.2.133.29","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.11.027"},{"key":"2025090709073938000_11.2.133.30","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2014.154"},{"key":"2025090709073938000_11.2.133.31","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s12664-018-0859-4","article-title":"Corticosteroids, nutrition, pentoxifylline, or fecal microbiota transplantation for severe alcoholic hepatitis","volume":"37","author":"Philips","year":"2018","journal-title":"Indian J Gastroenterol"},{"key":"2025090709073938000_11.2.133.32","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2000.20189"},{"key":"2025090709073938000_11.2.133.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.10.010"},{"key":"2025090709073938000_11.2.133.34","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/lt.24986","article-title":"Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: a multinational, prospective, controlled, randomized trial","volume":"24","author":"Thompson","year":"2018","journal-title":"Liver Transpl"},{"key":"2025090709073938000_11.2.133.35","unstructured":"Shakil I . Vital therapies shares dive as liver system fails trial. Reuters, 2018. Available: https:\/\/uk.reuters.com\/article\/us-vti-study\/vital-therapies-shares-dive-as-liver-system-fails-trial-idUKKCN1LS1M9 [Accessed 22 Jan 2019]."},{"key":"2025090709073938000_11.2.133.36","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20206"},{"key":"2025090709073938000_11.2.133.37","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.08.057"},{"key":"2025090709073938000_11.2.133.38","first-page":"1","article-title":"Selonsertib in combination with prednisolone for the treatment of severe alcoholic hepatitis: a phase 2 randomized controlled trial [abstract]","volume":"68","author":"Mathurin","year":"2018","journal-title":"Hepatology"},{"key":"2025090709073938000_11.2.133.39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105703"},{"key":"2025090709073938000_11.2.133.40","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1053\/j.gastro.2018.04.009","article-title":"Outcomes of early liver transplantation for patients with severe alcoholic hepatitis","volume":"155","author":"Lee","year":"2018","journal-title":"Gastroenterology"},{"key":"2025090709073938000_11.2.133.41","doi-asserted-by":"crossref","unstructured":"Lee BP , Vittinghoff E , Hsu C , et al . Predicting Low\u2010Risk for sustained alcohol use after early liver transplant for acute alcoholic hepatitis: the salt score. hepatology, 2018. Available: https:\/\/aasldpubs.onlinelibrary.wiley.com\/doi\/abs\/10.1002\/hep.30478 [Accessed 25 Jan 2019].","DOI":"10.1002\/hep.30478"}],"container-title":["Frontline Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/flgastro-2018-101104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T16:07:50Z","timestamp":1757261270000},"score":1,"resource":{"primary":{"URL":"https:\/\/fg.bmj.com\/lookup\/doi\/10.1136\/flgastro-2018-101104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,21]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2,10]]},"published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1136\/flgastro-2018-101104"],"URL":"https:\/\/doi.org\/10.1136\/flgastro-2018-101104","relation":{},"ISSN":["2041-4137","2041-4145"],"issn-type":[{"value":"2041-4137","type":"print"},{"value":"2041-4145","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,21]]}}}